ONKOprofil – Genetic Test

ONKOprofil is an advanced genetic test that allows assessment of the risk of hereditary cancers. The procedure is based on gene analysis using next-generation sequencing (NGS), which enables precise identification of genetic mutations associated with predisposition to various types of cancer. ONKOprofil is available in two variants: a panel for women and a panel for men, tailored to differences in hereditary cancer risk.

Purpose of the ONKOprofil Test

The aim of the ONKOprofil test is to identify mutations in genes associated with an increased risk of hereditary cancers. Knowing that such mutations are present makes it possible to introduce appropriate preventive measures, detect disease at an early stage and implement effective treatment. The test is particularly recommended for people with a family history of cancer.

Panel for Women

ONKOprofil for women includes analysis of 85 genes associated with the risk of developing 24 types of cancer. The most commonly assessed mutations include the BRCA1, BRCA2, TP53, PALB2 and MLH1 genes, which are associated with cancers such as:

• Breast cancer,
• Ovarian cancer,
• Endometrial cancer,
• Colorectal cancer,
• Pancreatic cancer.

The test makes it possible not only to identify the risk of developing cancer, but also to assess the hereditary nature of a mutation within the family, which may be of significant importance to the patient’s relatives.

Panel for Men

The panel designed for men includes analysis of 90 genes associated with an increased risk of developing 23 types of cancer. Particularly important mutations include those in the BRCA2, APC, MLH1 and RET genes, which are associated with cancers such as:

• Prostate cancer,
• Colorectal cancer,
• Stomach cancer,
• Kidney cancer,
• Thyroid cancer.

The analysis makes it possible to determine individual genetic predispositions and tailor a personalized prevention and health monitoring plan.

How the Test Is Performed

• Sample required for testing - the ONKOprofil test requires a venous blood sample collected on an outpatient basis. The procedure is quick and minimally invasive, and the blood sample is transported to a genetic laboratory for analysis.
• NGS testing method - next-generation sequencing (NGS) is an advanced technique that enables simultaneous analysis of multiple genes. Thanks to its high precision, NGS can identify both point mutations and larger gene rearrangements that may be responsible for an increased risk of cancer.

Clinical Significance of the Test

ONKOprofil provides important information about the risk of hereditary cancers. The test results may allow:

• Early implementation of preventive measures, such as regular imaging examinations or lifestyle changes.
• Planning an individualized health monitoring schedule.
• Making decisions regarding preventive surgery in cases of high risk, for example prophylactic mastectomy in patients with BRCA1/BRCA2 mutations.
• Educating the patient’s family members about their potential genetic risk.
  
  

ONKOprofil is a genetic test that supports informed management of health and cancer risk. Genetic analysis can identify predispositions that might otherwise remain undiagnosed. The test is intended for both women and men, and its results may have a significant impact on the health of the patient and their family.

We invite you to undergo the ONKOprofil test at Tartaczna 2 Medical Centre. The results can be discussed with our oncologist, Dr Magdalena Korożan.